Trial Profile
A phase III double-blind, placebo-controlled multicenter study of abciximab in patients undergoing high risk coronary angioplasty (EPIC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Abciximab (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Therapeutic Use
- Sponsors Janssen Biotech
- 19 Nov 2006 New trial record.